Summary of Orchestra BioMed FY Conference Call (March 03, 2026) Company Overview - **Company**: Orchestra BioMed (NasdaqGM:OBIO) - **Focus**: Development of innovative medical technologies, particularly in the fields of hypertension and coronary artery disease through partnerships with established companies like Medtronic and Terumo [1][2] Key Programs and Developments AVIM Therapy - **Indications**: Targets hypertensive heart disease and coronary artery disease, utilizing a pacemaker for delivery [3][4] - **Market Opportunity**: Estimated over $17 billion annual global opportunity in treating hypertension within the pacemaker population [5] - **Clinical Trials**: Actively enrolling in the BACKBEAT pivotal trial for AVIM therapy, with a goal to complete enrollment in 2026 and data readout expected in 2028 [4][24] - **Mechanism**: AVIM therapy modulates blood pressure by shortening the timing of atrial and ventricular contractions, leading to immediate and sustained blood pressure reduction [16][17] - **Clinical Data**: Demonstrated significant reductions in systolic blood pressure (average drop of 15.5 mmHg) and improvements in diastolic function in patients with isolated systolic hypertension [20][22] VIRTUE Sirolimus AngioInfusion Balloon - **Product Description**: A first-of-its-kind non-coated drug-eluting balloon designed for coronary artery disease treatment, leveraging a proprietary sirolimus formulation [25][26] - **Market Shift**: The market is transitioning from permanent implants like stents to drug-coated balloons, with a significant opportunity in both coronary and peripheral artery disease [25][26] - **Clinical Trials**: Enrolling patients in a pivotal trial against Boston Scientific's AGENT balloon, aiming for non-inferiority and potential superiority [30][44] - **Performance Metrics**: Achieved a low target lesion failure rate of 2.8% at one year, indicating strong clinical outcomes [29] Financial Position - **Funding**: Well-capitalized through late 2027, with recent transactions bringing in additional capital, including $21 million from the sale of Vivasure and $35 million in tranche payments from partnerships [7][8] - **Royalty Structure**: Potential royalties of $500 to $1,600 per device sold by Medtronic, with significant revenue opportunities anticipated from AVIM therapy [14][15] Strategic Partnerships - **Medtronic**: A key partner, holding over 50% of the global pacing market, with exclusive rights to commercialize devices incorporating AVIM therapy [15][16] - **Terumo**: Holds a right of first refusal for the VIRTUE product, with a recent investment of $65 million [30][31] Market Trends and Insights - **Hypertension and Heart Failure**: Elevated systolic blood pressure is a major driver of heart failure progression, with AVIM therapy positioned as a preventive treatment for patients at risk [34][35] - **Drug-Eluting Balloon Market**: Increasing adoption of drug-coated balloons in coronary procedures, particularly in Europe and Asia, with a growing recognition of the need for differentiated products [41][42] Conclusion - **Outlook**: 2026 is positioned as a pivotal year for Orchestra BioMed, with significant clinical trials underway and a strong financial foundation to support growth and innovation in the medical device sector [31][32]